查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864450

动脉粥状硬化药物市场依药物类别、给药途径、通路、剂型及最终用户划分－2025-2032年全球预测

Atherosclerosis Drugs Market by Drug Class, Administration Route, Distribution Channel, Dosage Form, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动脉粥状硬化药物市场将成长至 375.7 亿美元，复合年增长率为 5.85%。

主要市场统计数据
基准年 2024 238.2亿美元
预计年份：2025年 252.5亿美元
预测年份：2032年 375.7亿美元
复合年增长率 (%) 5.85%

全面介绍影响现代动脉粥状硬化治疗方法的临床创新、监管趋势和营运压力

动脉粥状硬化治疗领域融合了数十年的临床经验和生物医学创新浪潮，正在重新定义临床医生和医疗保健系统管理血脂和降低心血管风险的方式。生技药品、标靶治疗和製剂科学的进步与长期使用的口服药物并存，为临床医生建构了一套复杂的治疗工具。同时，监管、证据标准和支付方的期望也在不断变化，影响哪些干预措施能够被纳入配药清单和临床实践。在此背景下，商业和临床相关人员必须应对错综复杂的临床结果资料、安全性概况、生产考量和进入限制等诸多因素。

深入探讨正在重塑动脉粥状硬化药物治疗策略和商业性动态的技术进步、支付方期望以及不断演变的给药模式。

在科学突破和医疗服务模式不断发展的推动下，动脉粥状硬化药物领域正经历着变革性的转变。精准标靶化脂质代谢通道和单株抗体疗法的出现正在改变治疗模式，促使临床医生考虑新的治疗顺序和联合治疗策略。同时，数位健康工具和远端监测正在提高患者依从性，并实现更精细的风险分层，从而影响治疗方案的选择和管理。

对 2025 年修订的美国关税如何重塑动脉粥状硬化药物价值链的供应链韧性、筹资策略和商业规划进行策略分析。

2025年美国关税调整对动脉粥状硬化药物生态系统产生了多方面的影响，包括原料采购、生产决策和跨境分销策略。关税调整凸显了供应链本地化和双重筹资策略的重要性，以应对成本波动和合规性问题。製造商正在透过重新评估供应商合约、寻找替代供应商，以及在某些情况下将生产转移到贸易条款更可预测的地区来应对这些变化。

将药物类别特征、给药途径、剂型、分销管道和最终用户环境与商业和临床应用模式联繫起来的详细細項分析

细分市场分析揭示了不同药物类别和给药途径在临床、营运和商业性动态方面存在显着差异。在各类药物中，胆汁酸螯合剂，例如考来烯胺、考来维崙和考来替泊，仍被广泛应用，其长期使用取决于耐受性和患者依从性。同时，贝特类药物，包括非诺贝特和吉非贝齐，针对特定的血脂亚谱，在以降低三酸甘油酯为首要目标的临床环境中仍扮演着重要角色。烟碱酸，无论是缓释性或速释製剂，其独特的耐受性和剂量考量都会影响患者的选择。此外， Omega-3脂肪酸，以其二十二碳六烯酸 (DHA) 和二十碳五烯酸 (EPA) 的特征为特征，被定位为辅助性治疗，其在特定适应症方面的证据正在不断积累。 PCSK9抑制剂，例如阿利西尤单抗和依洛尤单抗，已经改变了高强度低密度脂蛋白胆固醇 (LDL-C) 管理策略，尤其适用于口服治疗未能达到目标的患者。同时，由于其广泛的证据基础和已确立的安全特性，他汀类药物（包括Atorvastatin、普伐他汀、rosuvastatin和Simvastatin）继续构成降血脂治疗的基石。

区域竞争和监管差异将导緻美洲、欧洲、中东和非洲以及亚太地区出现不同的准入策略、证据优先事项和商业性方法。

区域趋势将以不同的方式影响美洲、欧洲、中东和非洲以及亚太地区的临床实践、监管管道和商业性准入。在美洲，既定的临床指南和整合的支付方-服务提供方结构支持循证干预措施，而区域监管和报销管道则鼓励关注真实世界的有效性和长期安全性。相较之下，欧洲、中东和非洲的法规结构和报销环境各不相同，各国不同的价格谈判和卫生技术评估流程导致实施时间和进入策略有差异。

竞争策略、製造差异化和伙伴关係模式定义了那些在动脉粥状硬化领域提供持续临床和商业性价值的组织。

领先的动脉粥状硬化治疗主要企业正在推行多元化策略，力求在创新、生命週期管理和业务永续营运之间取得平衡。现有企业持续投资于产品改进、缓释性和联合治疗，以提高患者依从性和治疗效果；而专业公司则专注于高价值生技药品和标靶治疗，以应对持续存在的残余风险。策略联盟、授权协议和共同开发契约在寻求缩短产品上市时间、实现产品线多元化和共用研发风险的公司中日益普遍。

为加速产品推广和普及，提出切实可行的策略建议，旨在整合临床证据、供应链韧性和以支付方为中心的商业性执行。

产业领导者应采取整合临床差异化、切实可行的商业性执行和营运韧性的策略。首先，为满足监管机构和支付方的要求，应优先进行证据生成工作，兼顾随机对照试验的严谨性和真实世界疗效，投资于註册研究和纵向研究，以证明临床终点和长期耐受性方面的显着改善。其次，透过双重采购、选择性地域多角化生产和增强贸易合规能力来优化供应链设计，从而降低关税波动和物流中断的影响。第三，利用跨药物类别、给药途径、剂型、分销管道和终端用户环境的细分洞察，调整产品定位，使其与治疗属性、临床路径和支付方要求相符。

我们采用透明的混合方法研究框架，将主要专家见解与次要证据综合相结合，以严格描绘临床、商业性和营运动态。

本分析的调查方法融合了定性和定量方法，以确保证据基础的稳健性和透明度。主要研究包括对临床医生、支付方代表、供应链经理和行业高管进行专家访谈，以收集关于临床实践、报销驱动因素和营运限制的细緻观点。次要研究整合了同侪审查文献、监管指导文件、临床实验室註册资讯和公共卫生资料检验临床疗效、安全性讯号和指南演变。数据三角验证确保研究结果既反映了对照试验的证据，也反映了真实世界的经验。

简而言之，临床创新、支付方期望和营运韧性是支撑成功的动脉粥状硬化药物策略的支柱。

摘要，动脉粥状硬化药物领域的特点是持续性口服疗法与不断发展的生技药品之间动态的相互作用，而这种相互作用又受到不断变化的监管预期和商业性现实的影响。临床创新正在拓展临床医生可选择的治疗方案，但药物的普及应用取决于令人信服的真实世界数据、与支付共用的价值认知以及供应链的韧性。从生产策略到分销管道优化，营运灵活性将日益决定哪些治疗方法能够获得广泛且持续的应用。那些能够将科学差异化、务实的商业性执行以及积极的支付方沟通相结合的相关人员，将更有能力在控製成本和应对准入压力的同时，改善患者的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • PCSK9抑制剂对动脉粥状硬化治疗中竞争性定价和市场扩张的影响
  • siRNA疗法标靶降低脂蛋白(a)在动脉粥状硬化治疗的临床进展
  • 扩大贝培多酸和他汀类药物联合治疗的适用范围可提高患者遵从性和治疗效果。
  • 口服PCSK9抑制剂为动脉粥状硬化的治疗提供了注射生技药品的创新替代方案。
  • 透过采用基因谱分析和个人化医疗策略，优化动脉粥状硬化药物治疗方案，以适应个别患者的需求。
  • 将数位健康平台与远端监测结合，以提高动脉粥状硬化药物治疗方案的依从性
  • 生物类似单株抗体市场进入对动脉粥状硬化生技药品疗法的成本效益和可及性的影响

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 动脉粥状硬化药物市场（依药物类别划分）

  • 胆汁酸螯合剂
    • 考来烯胺
    • 科尔塞维拉姆
    • 科莱斯蒂波尔
  • 贝特类药物
    • 非诺贝特
    • 吉非贝齐
  • 烟碱酸
    • 缓释性
    • 立即发布
  • Omega-3脂肪酸
    • 二十二碳六烯酸
    • 二十碳五烯酸
  • PCSK9抑制剂
    • 阿利西尤单抗
    • 依洛尤单抗
  • 他汀类药物
    • Atorvastatin
    • 普伐他汀
    • rosuvastatin
    • Simvastatin

9. 依给药途径分類的动脉粥状硬化药物市场

  • 注射
    • 静脉注射
  • 口服
    • 胶囊
    • 药片

10. 动脉粥状硬化药物市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 动脉粥状硬化药物市场（依剂型划分）

  • 胶囊
  • 注射
  • 药片

第十二章 动脉粥状硬化药物市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

13. 各地区动脉粥状硬化药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 动脉粥状硬化药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国动脉粥状硬化药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • AstraZeneca PLC
    • Regeneron Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Johnson & Johnson
Product Code: MRR-F97DD5A7DBFE

The Atherosclerosis Drugs Market is projected to grow by USD 37.57 billion at a CAGR of 5.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.82 billion
Estimated Year [2025] USD 25.25 billion
Forecast Year [2032] USD 37.57 billion
CAGR (%) 5.85%

A comprehensive introduction outlining clinical innovations, regulatory dynamics, and operational pressures shaping modern therapeutic approaches to atherosclerosis

The therapy landscape for atherosclerosis blends decades of clinical experience with a wave of biomedical innovation that is redefining how clinicians and health systems approach lipid management and cardiovascular risk reduction. Advances in biologics, targeted therapies, and formulation science coexist with long-established oral agents, creating a complex therapeutic toolkit for clinicians. Meanwhile, regulatory scrutiny, evidence standards, and payer expectations continue to evolve, shaping which interventions gain traction in formularies and clinical practice. In this environment, commercial and clinical stakeholders must navigate a confluence of clinical outcomes data, safety profiles, manufacturing considerations, and access constraints.

In practice, care pathways are being reframed by precision medicine approaches, greater emphasis on real-world evidence, and a growing focus on long-term safety and tolerability in at-risk populations. These forces create opportunities for differentiated products that demonstrate meaningful clinical benefit, adherence advantages, or logistical efficiencies. At the same time, operational pressures such as supply chain resilience, pricing negotiations, and integration into multidisciplinary care teams influence how therapies are adopted and maintained. By synthesizing clinical trends with operational realities, stakeholders can identify strategic windows for product differentiation, lifecycle management, and partnership-driven expansion.

An in-depth exploration of technological advances, payer expectations, and delivery model evolution that are reshaping therapeutic strategies and commercial dynamics in atherosclerosis care

The landscape of atherosclerosis therapy is undergoing transformative shifts driven by scientific breakthroughs and evolving healthcare delivery models. Precision targeting of lipid pathways and the emergence of monoclonal antibody therapeutics have altered treatment paradigms, prompting clinicians to consider new sequencing and combination strategies. Concurrently, digital health tools and remote monitoring are improving patient adherence and enabling more nuanced risk stratification, which in turn affects treatment selection and longitudinal management.

Commercial models are also shifting as payers demand robust real-world outcomes and value-based arrangements that tie payment to demonstrable clinical benefit. Manufacturers are adapting by focusing on differentiated formulations, patient-support programs, and evidence generation beyond randomized controlled trials. Supply chain innovations and strategic manufacturing partnerships are helping to mitigate production bottlenecks for complex biologics while ensuring continuity of access for generic oral agents. Taken together, these changes are redefining competitive dynamics and creating pathways for both established and emerging therapies to deliver sustained clinical value in practice.

A strategic analysis of how revised United States tariff measures in 2025 have reshaped supply chain resilience, procurement strategy, and commercial planning across the atherosclerosis drug value chain

United States tariff policy changes in 2025 have produced layered effects across the atherosclerosis drug ecosystem, influencing raw material sourcing, manufacturing decisions, and cross-border distribution strategies. Tariff adjustments have increased the importance of supply chain localization and dual-sourcing strategies to manage cost volatility and regulatory compliance. Manufacturers have responded by reassessing supplier contracts, qualifying alternative vendors, and in some cases reallocating production footprints to jurisdictions with more predictable trade terms.

These trade-policy dynamics have also shaped commercial negotiations and pricing constructs, with payers and providers recalibrating procurement strategies to manage downstream cost pressures. For complex biologics and novel agents that rely on specialized components or high-value active pharmaceutical ingredients, tariff-driven cost increases have incentivized investments in vertical integration and long-term contracting. Meanwhile, established oral therapies with mature manufacturing bases have leaned into scale efficiencies and optimized logistics to preserve supply continuity.

Operationally, increased customs scrutiny and variability in duty assessments have elevated the role of trade compliance expertise within life sciences organizations. In response, teams have expanded scenario planning and stress-testing to understand how tariff permutations affect product launch timelines, portfolio prioritization, and global distribution choices. As a result, organizations that align regulatory strategy, procurement, and commercial planning are better positioned to navigate the cumulative impact of trade policy shifts without disrupting patient access and care delivery.

Granular segmentation insights linking drug class nuances, administration routes, dosage forms, distribution channels, and end-user settings to commercial and clinical adoption patterns

Segment-level insights reveal differentiated clinical, operational, and commercial dynamics across drug classes and modalities. Within drug classes, bile acid sequestrants such as cholestyramine, colesevelam, and colestipol continue to occupy a role where tolerability and adherence considerations determine long-term use, while fibrates including fenofibrate and gemfibrozil address specific lipid subprofiles and remain clinically relevant where triglyceride reduction is prioritized. Niacin in extended release and immediate release formulations presents distinct tolerability and dosing considerations that affect patient selection, and omega-3 fatty acids characterized by docosahexaenoic acid and eicosapentaenoic acid profiles are positioned as adjunctive options with evolving evidence for specific indications. PCSK9 inhibitors represented by alirocumab and evolocumab have altered high-intensity LDL management strategies, especially where patients do not reach targets with oral agents, and statins including atorvastatin, pravastatin, rosuvastatin, and simvastatin continue to form the backbone of lipid-lowering regimens given their broad evidence base and established safety profiles.

Administration routes and dosage forms further influence adoption and logistics. Injectable therapies, including those administered intravenously, demand distinct clinic workflows, cold-chain logistics, and patient-support programs, whereas oral therapies in capsule and tablet formats prioritize adherence support and simplifying regimens for ambulatory settings. Distribution channel dynamics show divergent opportunities across hospital pharmacy, online pharmacy, and retail pharmacy environments, with each channel presenting unique payer contracting considerations and patient access pathways. Dosage forms categorized as capsule, injection, and tablet intersect with end-user settings such as clinic, home care, and hospital to create nuanced adoption patterns where clinical setting, patient capability, and reimbursement frameworks determine the optimal therapeutic choice. These segmentation lenses collectively inform product positioning, lifecycle strategies, and commercial execution plans across varied healthcare delivery contexts.

Regional competitive and regulatory nuances that drive differentiated access strategies, evidence priorities, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical practice, regulatory pathways, and commercial access in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, well-established clinical guidelines and integrated payer-provider structures favor evidence-rich interventions, and regional regulatory and reimbursement pathways drive emphasis on real-world effectiveness and long-term safety. Conversely, Europe, Middle East & Africa present heterogeneous regulatory frameworks and reimbursement environments where country-level pricing negotiations and health technology assessment processes create varied adoption timelines and differentiated access strategies.

Asia-Pacific markets display a mix of rapid innovation adoption in select urban healthcare systems alongside broad demand for cost-effective oral therapies across diverse care settings. Regional manufacturing hubs and local regulatory reforms have encouraged regional supply chain optimization and in-market manufacturing partnerships. Across all regions, local clinical practice patterns, demographic risk profiles, and health system funding models influence which therapies gain traction, how patient support programs are structured, and where investments in real-world evidence generation will have the greatest impact. Consequently, regional commercial strategies must align regulatory engagement, pricing approaches, and evidence development to regional priorities in order to maximize clinical uptake and sustainable access.

Competitive corporate strategies, manufacturing differentiation, and partnership models that are defining which organizations deliver sustained clinical and commercial value in the atherosclerosis domain

Leading companies in the atherosclerosis space are pursuing multi-pronged strategies that balance innovation with lifecycle management and operational resilience. Established players continue to invest in incremental product improvements, extended-release formulations, and combination approaches that enhance adherence and therapeutic effect, while specialty firms focus on high-value biologics and targeted agents that address persistent residual risk. Strategic alliances, licensing arrangements, and co-development agreements are increasingly common as organizations seek to accelerate time to market, diversify pipelines, and share development risk.

Manufacturing and supply chain capabilities emerge as critical differentiators, especially for complex injectables and monoclonal antibodies that require specialized production infrastructure and stringent cold-chain logistics. Companies that integrate manufacturing planning with commercial forecasting and regulatory strategy secure improved launch readiness and continuity of supply. Moreover, an intensified focus on value demonstration has prompted greater investment in post-launch studies, registries, and outcomes research to support payer engagement. Finally, digital health partnerships and patient support ecosystems are being leveraged to improve adherence, monitor safety signals, and strengthen real-world value propositions, reinforcing a shift toward holistic product offerings rather than standalone molecules.

Actionable strategic recommendations for aligning clinical evidence, supply chain resilience, and payer-focused commercial execution to accelerate product adoption and access

Industry leaders should adopt an integrated strategy that aligns clinical differentiation with pragmatic commercial execution and operational resilience. First, prioritize evidence generation that balances randomized trial rigor with real-world outcomes to satisfy both regulatory bodies and payers; invest in registries and longitudinal studies that demonstrate meaningful improvement in clinical endpoints and long-term tolerability. Second, optimize supply chain design through dual sourcing, selective regionalization of manufacturing, and strengthened trade compliance capabilities to mitigate the impact of tariff volatility and logistical disruptions. Third, tailor product positioning by leveraging segmentation insights across drug class, administration route, dosage form, distribution channel, and end-user setting to match therapeutic attributes to clinical pathways and payer requirements.

Further, pursue partnerships that accelerate access and broaden care delivery channels, integrating digital adherence solutions and patient-support services to enhance persistence and outcomes. Engage early with payers to explore value-based arrangements and to co-develop evidence that aligns with reimbursement criteria. Finally, invest in commercial capability building-equipping field teams with outcomes-driven messaging, payer-engagement tools, and localized launch playbooks-to ensure that clinical advantages translate into sustained uptake across diverse healthcare settings. Taken together, these approaches will help organizations navigate complexity while maximizing patient benefit and commercial performance.

A transparent mixed-methods research framework combining primary expert insight and secondary evidence synthesis to rigorously map clinical, commercial, and operational dynamics

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure a robust, transparent evidence base. Primary research components include expert interviews with clinicians, payer representatives, supply chain leaders, and industry executives to capture nuanced perspectives on clinical practice, reimbursement drivers, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public health datasets to validate clinical efficacy, safety signals, and guideline evolution. Data triangulation ensured that insights reflect both controlled trial evidence and real-world experience.

Analytical frameworks employed include segmentation mapping across therapeutic class, administration route, distribution channel, dosage form, and end-user setting to identify adoption patterns and unmet needs. Scenario analysis and sensitivity testing were used to explore how variations in trade policy, reimbursement criteria, and supply chain disruptions affect strategic priorities. Quality assurance procedures included cross-validation of interview findings with literature evidence and iterative expert review to refine conclusions. This mixed-methods approach produces an actionable synthesis that stakeholders can apply to clinical development strategy, market access planning, and operational decision-making while maintaining methodological rigor and reproducibility.

A concise conclusion synthesizing clinical innovation, payer expectations, and operational resilience as the pillars for successful atherosclerosis therapy strategies

In sum, the atherosclerosis therapeutic arena is defined by a dynamic interplay between enduring oral therapies and advancing biologics, underpinned by shifting regulatory expectations and commercial realities. Clinical innovation is expanding the toolkit available to clinicians, but adoption depends on convincing real-world evidence, payer-aligned value demonstrations, and supply chain robustness. Operational agility-from manufacturing strategy to distribution channel optimization-will increasingly determine which therapies achieve broad, sustained use. Stakeholders that blend scientific differentiation with pragmatic commercial execution and proactive payer engagement will be best positioned to improve patient outcomes while managing cost and access pressures.

As the environment continues to evolve, decision-makers should emphasize evidence generation that resonates with payers and clinicians, develop resilient supply networks that insulate launches from trade perturbations, and tailor regional strategies to local regulatory and clinical contexts. By doing so, organizations can convert clinical promise into tangible improvements in cardiovascular risk management and construct durable commercial advantages that support future innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of PCSK9 inhibitors on competitive pricing and market expansion in atherosclerosis treatment
  • 5.2. Clinical progress of siRNA therapies targeting lipoprotein(a) reduction in atherosclerosis management
  • 5.3. Expansion of combination regimens with bempedoic acid and statins to enhance patient adherence and outcomes
  • 5.4. Emergence of oral PCSK9 inhibitors as a disruptive alternative to injectable biologics in atherosclerosis care
  • 5.5. Adoption of genetic profiling and personalized medicine strategies to tailor atherosclerosis drug therapies to individual patients
  • 5.6. Integration of digital health platforms and remote monitoring to improve adherence in atherosclerosis pharmacotherapy programs
  • 5.7. Impact of biosimilar monoclonal antibody entries on affordability and access to atherosclerosis biologic therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atherosclerosis Drugs Market, by Drug Class

  • 8.1. Bile Acid Sequestrants
    • 8.1.1. Cholestyramine
    • 8.1.2. Colesevelam
    • 8.1.3. Colestipol
  • 8.2. Fibrates
    • 8.2.1. Fenofibrate
    • 8.2.2. Gemfibrozil
  • 8.3. Niacin
    • 8.3.1. Extended Release
    • 8.3.2. Immediate Release
  • 8.4. Omega-3 Fatty Acids
    • 8.4.1. Docosahexaenoic Acid
    • 8.4.2. Eicosapentaenoic Acid
  • 8.5. PCSK9 Inhibitors
    • 8.5.1. Alirocumab
    • 8.5.2. Evolocumab
  • 8.6. Statins
    • 8.6.1. Atorvastatin
    • 8.6.2. Pravastatin
    • 8.6.3. Rosuvastatin
    • 8.6.4. Simvastatin

9. Atherosclerosis Drugs Market, by Administration Route

  • 9.1. Injectable
    • 9.1.1. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Atherosclerosis Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Atherosclerosis Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Atherosclerosis Drugs Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Atherosclerosis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atherosclerosis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atherosclerosis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Amgen Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Sanofi S.A.
    • 16.3.5. AstraZeneca PLC
    • 16.3.6. Regeneron Pharmaceuticals, Inc.
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Bayer AG
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET